Delving into the Latest Updates on Atezolizumab with Synapse

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

Anti-PDL-1-Genentech/Roche, Atezolizumab (Genetical Recombination), Atezolizumab (genetical recombination) (JAN)

+ [11]

Target

PDL1

Action

inhibitors

Mechanism

PDL1 inhibitors(Programmed death-ligand 1 inhibitors)

Therapeutic Areas

NeoplasmsImmune System DiseasesDigestive System Disorders+ [11]

Active Indication

Extranodal NK-T-Cell LymphomaAdvanced Lung Non-Small Cell CarcinomaBreast Cancer+ [149]

Inactive Indication

Adenocarcinoma of large intestineAdvanced Bile Duct CarcinomaAdvanced biliary tract cancer+ [101]

Originator Organization

Genentech, Inc.

Universitair Medisch Centrum Groningen

Active Organization

Roche Registration GmbH

Roche China Holding Ltd.Hoffmann-La Roche, Inc.

+ [20]

Inactive Organization

Kymab Ltd.

Sanofi

Pfizer Inc.

+ [14]

License Organization

NeoImmuneTech, Inc.

Harpoon Therapeutics, Inc.Novocure, Inc.

+ [26]

Drug Highest PhaseApproved

First Approval Date

United States (18 May 2016),

Transitional Cell Carcinoma

RegulationBreakthrough Therapy (United States), Fast Track (United States), Accelerated Approval (United States), Orphan Drug (United States), Priority Review (China), Orphan Drug (Japan), Orphan Drug (Australia), Priority Review (Australia), Conditional marketing approval (China)

Login to view timeline

Structure/Sequence

Sequence Code 122091L

Source: *****

Sequence Code 4720027H

Source: *****

This phase III trial compares the effect of atezolizumab (or atezolizumab and recombinant human hyaluronidase) to standard observation for preventing cancer return after surgery (recurrence) in patients who have undergone a complete surgical removal (resection) of stage I non-small cell lung cancer (NSCLC). Patients who have undergone resection for lung cancer are typically followed by observation or active surveillance, which involves closely watching a patient's condition but not giving treatment unless there are changes in test results. During active surveillance, patients are given certain exams and tests done on a regular schedule. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Atezolizumab and recombinant human hyaluronidase is a formulation of atezolizumab combined with an enzyme called hyaluronidase, which helps increase tissue absorption of the drug. Giving atezolizumab or atezolizumab and recombinant human hyaluronidase after resection may be effective for preventing NSCLC recurrence, and may be a better approach to treating patients with stage I NSCLC than the usual observation approach.

Start Date02 Mar 2027

Sponsor / Collaborator

National Cancer Institute

NCT07170592

/ Not yet recruitingPhase 1

A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Combination With Hydroxyurea or Hydroxyurea/Atezolizumab in Treatment-refractory Solid Tumor Patients

This clinical trial aims to determine whether the administration of the investigational drug OTS-412, OTS-412 in combination with hydroxyurea or hydroxyurea/atezolizumab is safe and effective for patients with various types of cancer.

Start Date01 Jan 2027

Sponsor / Collaborator

Bionoxx, Inc.

NCT07796100

/ Not yet recruitingPhase 3

A Randomized, Open-Label, Phase 3 Study of ZL-1310, a DLL3 Antibody-drug Conjugate (ADC) in Combination With a Checkpoint Inhibitor Compared to Standard of Care Platinum Based Chemotherapy With a Checkpoint Inhibitor as First-line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer

The purpose of this study is to evaluate the efficacy and safety of ZL-1310 in combination with a checkpoint inhibitor compared to standard first-line therapy in participants with Extensive-Stage Small Cell Lung Cancer.

Start Date31 Dec 2026

Sponsor / Collaborator

Zai Lab (Shanghai) Co., Ltd.

[+1]

100 Clinical Results associated with Atezolizumab

Login to view more data

100 Translational Medicine associated with Atezolizumab

Login to view more data

100 Patents (Medical) associated with Atezolizumab

Login to view more data

4,384

Literatures (Medical) associated with Atezolizumab

01 Jan 2027·WATER RESEARCH

A scalable Zn-Mn-enabled catalytic ozonation process for robust drinking water purification

Article

Author: Hou, Congyu ; Zhang, Xihui ; Wang, Yanyi ; Yang, Yulong ; Zhang, Jiahui ; Deng, Yuepeng ; Tang, Shengyin ; Tang, Tianhao

In this study, a highly active oxygen-vacancy-rich Zn-Mn oxide catalyst (ZnMnO₃) and its kilogram-scalable form (ZnMn@CMs) were synthesized via a simple co-precipitation method for catalytic ozonation of drinking water, targeting enhanced removal of assimilable organic carbon precursors (AOC‑P) and trace emerging contaminants (ECs). Catalytic performance was evaluated using atrazine (ATZ) degradation as a model reaction, together with AOC-P and trace ECs removal under low O₃ dosages in real drinking water. The catalytic mechanism was elucidated through material characterization, oxygen vacancies (OVs) and reactive oxygen species (ROS) identification, Zn-Mn synergistic effects, and Fourier transform ion cyclotron resonance mass spectrometry analysis of ROS-dissolved organic matter interactions. Results demonstrated that OVs integrate Zn-Mn dual active sites and promote interfacial electron transfer, enhancing the exposure of hydrated hydroxyl groups at Zn sites and the adsorption of O₃ at Mn sites. Meanwhile, OVs could also be served as electron donors to activate O₂ for H₂O₂ generation, strengthening ROS transformation. Therefore, ZnMnO₃ with abundant OVs exhibited superior ozonation performance, achieving 96.71% ATZ degradation and a 7.80-fold rate enhancement over sole ozonation, along with excellent anion tolerance and cycling stability. In real drinking water treatment, the synergistic action of multiple ROS enables the O₃/ZnMn@CMs process to achieve outstanding removal efficiency for AOC-P (>90%), fluorescent components (>60%) and trace pharmaceuticals and personal care products (>66%), while maintaining excellent long-term catalytic stability (≥20 days) and low metal leaching. The scalable, oxygen-vacancy-rich Zn-Mn oxide catalyst developed herein provides an effective strategy for safeguarding high‑quality drinking water.

31 Dec 2026·JOURNAL OF MEDICAL ECONOMICS

Cost-effectiveness analysis of atezolizumab and bevacizumab as first-line systemic therapy in unresectable hepatocellular carcinoma in Malaysia

Article

Author: Chaiyakunapruk, Nathorn ; Patikorn, Chanthawat ; Sulaiman Shah, Audi Adawiah ; Wong, Yoke Fui ; Mohamed, Rosmawati

AIM:

This study aims to evaluate the cost-effectiveness of atezolizumab plus bevacizumab as first-line systemic therapy for unresectable hepatocellular carcinoma (uHCC) in Malaysia, compared with the current standard treatments in the Malaysian Ministry of Health (MOH) to inform public healthcare decision‑making.

MATERIALS AND METHODS:

A cost-effectiveness analysis was conducted from the MOH perspective, following the national pharmacoeconomic guidelines (2019). The study compared atezolizumab plus bevacizumab with sorafenib and lenvatinib, respectively, using a partitioned survival model to project health outcomes and costs over a lifetime horizon. Clinical efficacy data were sourced from published trials and network meta-analyses. Cost inputs reflected local healthcare resource use and prices, using 2024 Malaysian Ringgit values inflated via the Consumer Price Index for Health. Costs and outcomes were discounted at 3% annually. Deterministic and probabilistic sensitivity analyses were performed to assess the impact of key parameter uncertainties on the results.

RESULTS:

Atezolizumab plus bevacizumab provided the highest quality-adjusted life years (QALYs) and life years compared to sorafenib and lenvatinib. Sorafenib was dominated by lenvatinib due to lower QALYs and higher costs and excluded from further analysis. Compared to lenvatinib, atezolizumab plus bevacizumab yielded 0.873 additional QALYs and RM 44,863 additional cost, resulting in an incremental cost-effectiveness ratio (ICER) of RM 51,399 per QALY gained (∼0.906 GDP/capita at Malaysia's 2024 GDP/capita RM 56,734).

CONCLUSIONS:

Atezolizumab plus bevacizumab is cost-effective compared to lenvatinib and sorafenib across willingness-to-pay (WTP) values of one to three times Malaysia's GDP per capita. These findings provide evidence to inform public health policy that expanding funding and adoption of atezolizumab plus bevacizumab is likely to improve health outcomes cost-effectively.

31 Dec 2026·Human Vaccines & Immunotherapeutics

Cost‑effectiveness of first‑line immunotherapy-based combination regimens for advanced renal cell carcinoma in China and the United States

Article

Author: Yan, Chunyan ; Zhao, Quan ; Li, Jiayan ; Diao, Ruigang ; Gao, Yuan ; Li, Zhengxiong

Immunotherapy‑based combination regimens provide significant clinical benefits but impose substantial economic burdens on national healthcare systems. This study assessed the cost-effectiveness of immunotherapy‑based combination regimens as first-line treatments for advanced renal cell carcinoma (aRCC) in China and the United States (US). A partitioned survival model was developed to evaluate the cost-effectiveness of all approved regimens with a lifetime horizon. The primary outcomes were total costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios (ICERs). Sensitivity analyses were performed to evaluate model uncertainty. Compared to the sunitinib regimen, the ICERs for the toripalimab plus axitinib (T + A), nivolumab plus ipilimumab (N + I), lenvatinib plus pembrolizumab (L + P), pembrolizumab plus axitinib (P + A), nivolumab plus cabozantinib (N + C), avelumab plus axitinib (A + A) and atezolizumab plus bevacizumab (A + B) regimens in China were $64,536.98/QALY, $135,593.25/QALY, $174,956.58/QALY, $231,908.95/QALY, $728,876.75/QALY, $1,232,070.43/QALY, and $2,496,799.42/QALY, respectively. The ICERs for the N + I, T + A, N + C, P + A, L + P, A + A, and A + B regimens in the US were $160,243.50/QALY, $468,156.65/QALY, $804,963.69/QALY, $907,549.79/QALY, $2,170,769.66/QALY, $2,623,809.39/QALY, and $12,712,147.95/QALY, respectively. Probabilistic sensitivity analyses indicated that the probability of cost-effectiveness corresponding to N + I vs. sunitinib was 33.6% in the US. In China and the US, none of the seven first-line immunotherapy-based combination regimens was cost-effective compared with sunitinib for aRCC.

1,722

News (Medical) associated with Atezolizumab

29 Sep 2026

·www.biospace.com

Zai Lab to Present First Global Data from Clinical Trial Evaluating Zocilurtatug Pelitecan (Zoci) As First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

Poster presentation at ESMO Congress 2026 will highlight findings from trial of zoci in combination with atezolizumab with and without carboplatin Data adds to body of evidence supporting zoci as a potential backbone antibody-drug conjugate in first-line combination regimens for ES-SCLC Investor conference call and webcast to discuss data being presented at ESMO and zoci clinical trial plans scheduled for Friday, October 23 at 8:00 a.m. ET / 8:00 p.m. HKT SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that global data from a clinical trial evaluating zocilurtatug pelitecan (zoci, formerly ZL-1310) for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC) will be shared for the first time at the European Society for Medical Oncology (ESMO) Congress 2026 taking place October 23-27, 2026, in Madrid. Zoci is a novel, potential first-in-class antibody-drug conjugate (ADC), that targets Delta-like ligand 3 (DLL3), a validated therapeutic target that is overexpressed in SCLC and is generally associated with poor clinical outcomes. The Phase 1b/1c cohort of the global trial is exploring the safety and efficacy of zoci in combination with atezolizumab with or without carboplatin. “We look forward to sharing results from this trial evaluating zoci as first-line therapy for small cell lung cancer, one of the most aggressive and lethal solid tumors,” said Rafael G. Amado, M.D., President, Head of Global Research and Development at Zai Lab. “We continue to be encouraged by zoci’s potential best-in-class safety profile, coupled with compelling systemic and intracranial efficacy that support zoci monotherapy as a potential new standard of care in previously treated ES-SCLC, as well as a backbone ADC in first-line combination regimens, including those that reduce the burden of chemotherapy.” ESMO 2026 zoci poster details: Title: ZL 1310 (DLL3 ADC) plus Atezolizumab ± Carboplatin in extensive-stage small cell lung cancer: Part 1b/1c results from Study ZL 1310-001 Session Title: SCLC Date/Time: October 26, 2026; 12:00-12:45 CEST Location: Poster Area – Hall 5 Poster Board Number: 3817P Abstract Number: 1569 Details regarding the webcast and conference call are as follows: Date/Time: Friday, October 23, 2026, at 5:00 a.m. PT / 8:00 a.m. ET / 8:00 p.m. HKT Registration available at: Webcast presentation (preferred): Dial-in: Presenters: Rafael G. Amado, M.D., President, Head of Global Research and Development, Zai Lab; Pedro Rocha, M.D., Ph.D, MSc, Medical Oncology Department, Vall d’Hebron University Hospital About Zai Lab Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States. We are focused on discovering, developing, and commercializing innovative products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. Our goal is to leverage our competencies and resources to positively impact human health. For additional information about Zai Lab, please visit or follow us at or . Zai Lab Forward-Looking Statements This press release contains forward-looking statements relating to our future expectations, plans, and prospects, for Zai Lab, including, without limitation, statements relating to our prospects and plans for developing and commercializing zocilurtatug pelitecan (zoci; ZL-1310), the potential benefits of zocilurtatug pelitecan (zoci; ZL-1310) and the potential treatment of small cell lung cancer, other neuroendocrine carcinomas, and solid tumors. All statements, other than statements of historical fact, included in this press release are forward-looking statements, and can be identified by words such as “aim,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “plan,” “possible,” “potential,” “will,” “would,” and other similar expressions. Such statements constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees or assurances of future performance. Forward-looking statements are based on our expectations and assumptions as of the date of this press release and are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements. We may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in our forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by forward-looking statements as a result of various important factors, including but not limited to (1) our ability to successfully commercialize and generate revenue from our approved products, (2) our ability to obtain funding for our operations and business initiatives, (3) the results of our clinical and pre-clinical development of our product candidates, (4) the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approvals of our product candidates, (5) risks related to doing business in China, and (6) other factors identified in our most recent annual and quarterly reports and in other reports we have filed with the U.S. Securities and Exchange Commission (SEC). We anticipate that subsequent events and developments will cause our expectations and assumptions to change, and we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release. Our SEC filings can be found on our website at and on the SEC’s website at . Contacts For more information, please contact: Investor Relations: Christine Chiou / Cyan Liu +1 (917) 886-6929 / +86 195 3130 8895 christine.chiou1@zailaboratory.com / cyan.liu@zailaboratory.com Media: Shaun Maccoun / Xiaoyu Chen +1 (857) 270-8854 / +86 185 0015 5011 shaun.maccoun@zailaboratory.com / xiaoyu.chen@zailaboratory.com

ADC

25 Sep 2026

·pmlive.com

MHRA approves Pharma Mar’s lurbinectedin for extensive-stage small cell lung cancer

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Pharma Mar’s lurbinectedin (Zepzelca) to treat adults with extensive-stage small cell lung cancer (SCLC). The treatment is in combination with atezolizumab as maintenance treatment in adults whose cancer has not progressed following first-line induction therapy with atezolizumab, carboplatin and etoposide. Lurbinectedin works by attaching to DNA inside cancer cells. This damages the DNA and interferes with the growth and multiplication of cancer cells, leading to cancer cell death. It also reduces the activity of certain immune cells that help tumours grow. The treatment is given as an intravenous infusion over one hour. The recommended dose is administered once every 21 days. This approval was based on a main study involving 483 adults with extensive-stage SCLC. Patients receiving lurbinectedin in combination with atezolizumab as maintenance treatment lived for an average of 13.2 months, compared with 10.6 months for those receiving atezolizumab alone. Patients receiving lurbinectedin plus atezolizumab also lived for an average of 5.4 months without their disease getting worse, compared with 2.1 months for those receiving atezolizumab alone. Julian Beach, MHRA Interim Executive Director of Healthcare Quality and Access, said: “The approval of lurbinectedin provides a new treatment option for adults with extensive-stage small cell lung cancer whose disease has not progressed following initial treatment with atezolizumab, carboplatin and etoposide.

Clinical ResultDrug Approval

22 Sep 2026

·www.biospace.com

Signatera™ Receives Regulatory Approval in Japan as a Companion Diagnostic in Muscle-Invasive Bladder Cancer

Second PMDA approval for Signatera in three months and first PMDA-approved CDx in MRD-guided care; commercial launch expected in 1H’27, pending final reimbursement and pricing AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that its Signatera test has received regulatory approval from Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) as a companion diagnostic (CDx) in muscle-invasive bladder cancer (MIBC). This approval supports the use of the Signatera test to guide adjuvant atezolizumab (Tecentriq®) treatment decisions in patients with MIBC. Natera expects to commercially launch Signatera for MIBC in Japan in the first half of 2027, following the PMDA’s approval of atezolizumab in MIBC. Regulatory approval was supported by data from IMvigor011, a randomized, double-blind phase III clinical trial that evaluated Signatera-guided adjuvant atezolizumab in patients with MIBC. The trial included more than 20 participating sites in Japan, giving Japanese clinicians firsthand experience with Signatera-guided treatment in this setting. This marks Signatera’s second PMDA authorization in Japan, after receiving approval in colorectal cancer in June 2026. It follows the U.S. Food and Drug Administration's (FDA) approval of Signatera as a CDx for adjuvant atezolizumab in MIBC (and the approval by the FDA of atezolizumab), as well as the recently published Category 1 recommendation for MRD-guided adjuvant atezolizumab in the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines for Bladder Cancer. Bladder cancer affects more than 34,000 people in Japan each year, 1 with approximately 20–25% of newly diagnosed cases classified as muscle-invasive. 2 MIBC carries a higher risk of recurrence and greater treatment complexity than earlier-stage disease, underscoring the need for precision tools that can help clinicians individualize treatment decisions in the adjuvant setting. “We look forward to launching this second Signatera MRD indication in Japan, giving patients with muscle-invasive bladder cancer a proven diagnostic tool to guide treatment decisions in the first year after surgery,” said Alexey Aleshin, M.D., corporate chief medical officer and general manager of oncology, Natera. “We value our growing partnership with the Japanese oncology community, which has been a leader in adopting MRD into clinical trials and into clinical practice.” References World Cancer Research Fund International. Bladder cancer statistics. Accessed June 26, 2026. Gakis G. Management of Muscle-invasive Bladder Cancer in the 2020s: Challenges and Perspectives. Eur. Urol. Focus. 2020;6(4):632–638. About Natera Natera is a global leader in cell-free DNA and precision medicine, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are supported by more than 400 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California, and through Foresight Diagnostics, its subsidiary, operates an ISO 27001-certified and CAP-accredited laboratory certified under CLIA in Boulder, Colorado. For more information, visit . Forward-Looking Statements All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera’s plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera’s expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to our efforts to develop and commercialize new product offerings, whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy, and performance of our tests, or of the benefits of our tests and product offerings to patients, providers, and payers. Additional risks and uncertainties are discussed in greater detail in "Risk Factors" in Natera’s recent filings on Forms 10-K and 10-Q, and in other filings Natera makes with the SEC from time to time. These documents are available at and . Notes Tecentriq® (atezolizumab) is a registered trademark of Genentech, a member of the Roche Group. Contacts Investor Relations: Mike Brophy, CFO, Natera, Inc., investor@natera.com Media: Lesley Bogdanow, VP of Corporate Communications, Natera, Inc., pr@natera.com

Phase 3Drug Approval

100 Deals associated with Atezolizumab

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D10773	Atezolizumab	L01XC32	DB11595

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Extranodal NK-T-Cell Lymphoma	Japan	Chugai Pharmaceutical Co., Ltd.	19 Sep 2025
Advanced Lung Non-Small Cell Carcinoma	European Union	Roche Registration GmbH	25 Jul 2024
Advanced Lung Non-Small Cell Carcinoma	Iceland	Roche Registration GmbH	25 Jul 2024
Advanced Lung Non-Small Cell Carcinoma	Liechtenstein	Roche Registration GmbH	25 Jul 2024
Advanced Lung Non-Small Cell Carcinoma	Norway	Roche Registration GmbH	25 Jul 2024
Breast Cancer	Canada	F. Hoffmann-La Roche Ltd.	13 Mar 2024
Alveolar Soft Part Sarcoma	United States	Genentech, Inc.	09 Dec 2022
PD-L1 positive Non-Small Cell Lung Cancer	Japan	Chugai Pharmaceutical Co., Ltd.	26 May 2022
BRAF V600 mutation-positive Melanoma	United States	Genentech, Inc.	30 Jul 2020
PD-L1 positive Triple Negative Breast Cancer	Japan	Chugai Pharmaceutical Co., Ltd.	19 Jan 2018
Advanced Hepatocellular Carcinoma	European Union	Roche Registration GmbH	20 Sep 2017
Advanced Hepatocellular Carcinoma	Iceland	Roche Registration GmbH	20 Sep 2017
Advanced Hepatocellular Carcinoma	Liechtenstein	Roche Registration GmbH	20 Sep 2017
Advanced Hepatocellular Carcinoma	Norway	Roche Registration GmbH	20 Sep 2017
Advanced Triple-Negative Breast Carcinoma	European Union	Roche Registration GmbH	20 Sep 2017
Advanced Triple-Negative Breast Carcinoma	Iceland	Roche Registration GmbH	20 Sep 2017
Advanced Triple-Negative Breast Carcinoma	Liechtenstein	Roche Registration GmbH	20 Sep 2017
Advanced Triple-Negative Breast Carcinoma	Norway	Roche Registration GmbH	20 Sep 2017
Extensive stage Small Cell Lung Cancer	European Union	Roche Registration GmbH	20 Sep 2017
Extensive stage Small Cell Lung Cancer	Iceland	Roche Registration GmbH	20 Sep 2017

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Mismatch repair-deficient Colonic Cancer	NDA/BLA	Australia	Roche Products Pty Ltd.	08 Apr 2026
Muscle Invasive Bladder Carcinoma	NDA/BLA	Japan	Chugai Pharmaceutical Co., Ltd.	28 Jan 2026
Bladder Cancer	NDA/BLA	China	Roche Holding AG	25 Feb 2019
Lymphoproliferative Disorders	Phase 3	United Kingdom	Hoffmann-La Roche Ltd.	25 Oct 2023
Melanoma	Phase 3	United Kingdom	Hoffmann-La Roche Ltd.	25 Oct 2023
Microsatellite instability-high cancer	Phase 3	United Kingdom	Hoffmann-La Roche Ltd.	25 Oct 2023
Turcot Syndrome	Phase 3	United Kingdom	Hoffmann-La Roche Ltd.	25 Oct 2023
Locally advanced breast cancer	Phase 3	United States	Roche China Holding Ltd.	29 Mar 2021
Locally advanced breast cancer	Phase 3	United States	F. Hoffmann-La Roche Ltd.	29 Mar 2021
Locally advanced breast cancer	Phase 3	United States	Roche Diagnostics GmbH	29 Mar 2021

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05359861 (CHS-388-201 \| phase 2 study of triplet blockade of the IL-27, PD-(L)1, and VEGF pathways with casdozokitug (casdozo, SRF388) in combination with atezolizumab (atezo) and bevacizumab (bev) in patients with unresectable, locally advanced, or metastatic hepatocellular carcinoma (uHCC), CTgov)	Phase 2	Metastatic hepatocellular carcinoma	30	Casdozokitug+Atezolizumab+Bevacizumab (Casdozokitug + Atezolizumab + Bevacizumab)	vrsmvbesmm = astfzwtake znfjgxjcfb (caaoizjyxl, anfsqgofmc - xlkztnvbkr) View more	-	01 Oct 2026
				Casdozokitug+Atezolizumab+Bevacizumab (Casdozokitug + Atezolizumab + Bevacizumab: Participants With CR)	aqptavsdoo(nbvyaimhli) = tyvqhpohwe pavrqciqjk (vqvupvwnbu, 1.4513)
NCT05908786 (CTgov)	Phase 1/2	Hepatocellular Carcinoma	62	Atezolizumab+Bevacizumab (Atezolizumab + Bevacizumab)	bmefofsptp = khxzcaykss wcwgaxuuxv (kwtiqzvpqz, zfgxqipsqt - ktugulcrio) View more	-	15 Sep 2026
				Atezolizumab+Bevacizumab+Tiragolumab (Atezolizumab + Bevacizumab + Tiragolumab)	bmefofsptp = rwzbbwlfai wcwgaxuuxv (kwtiqzvpqz, lmuvwdsqwd - tiiazupplr) View more
NCT04302025 (NAUTIKA1, WCLC2026)	Phase 2	Non-Small Cell Lung Cancer Neoadjuvant ROS1+ \| NTRK+ \| PD-L1+	15	Entrectinib	yvylzvqnsg(rvsprfvmwe) = vgflxqcyis kqcjnswvdg (toxgsyzuwa ) View more	Positive	12 Sep 2026
				Entrectinib (NTRK+ NSCLC)	yvylzvqnsg(rvsprfvmwe) = tclvfvkjho kqcjnswvdg (toxgsyzuwa ) View more
WCLC2026	Not Applicable	Extensive stage Small Cell Lung Cancer First line	97	Platinum- etoposide-atezolizumab	bgxvbuhryq(ofglsqwynm) = fmeqcmpvlt ovfdqapadg (bnsywyldby ) View more	Positive	12 Sep 2026
				Platinum- etoposide-atezolizumab (irAE-negative)	bgxvbuhryq(ofglsqwynm) = ocmeyrhrpi ovfdqapadg (bnsywyldby ) View more
WCLC2026	Not Applicable	Extensive stage Small Cell Lung Cancer First line	97	Carboplatin-Etoposide-Atezolizumab	qxjhkucncg(lbrjddbrdh) = ehiduoiivp ryghqgzfwz (kulqzatgee ) View more	Positive	12 Sep 2026
NCT02008227 (OAK, WCLC2026)	Phase 3	Non-Small Cell Lung Cancer tumor neoantigen positive (TN+)	103	Atezolizumab	grdxucwpyn(mdpxadyysi): HR = 0.34 (95.0% CI, 0.21 - 0.57), P-Value = <0.001	Positive	12 Sep 2026
				Docetaxel
NCT03456063 (IMpower030, WCLC2026)	Phase 3	Non-small cell lung cancer stage IIIB Adjuvant	397	Atezolizumab + platinum-based chemotherapy	jshwiyhuiu(ektxqnkoui) = bsagnzhdbf cbtrpwdtkl (rycjojftyk ) View more	Positive	12 Sep 2026
				Placebo + platinum-based chemotherapy	jshwiyhuiu(ektxqnkoui) = oytuywbgmb cbtrpwdtkl (rycjojftyk ) View more
NCT02763579 (IMpower133, WCLC2026)	Phase 3	Extensive stage Small Cell Lung Cancer First line B7-H3	462	atezolizumab plus carboplatin/etoposide (ACE)	kwgyngnmvc(hhyxwcdgby) = kjlrvikuny vdcvvnswsn (tlvsybylgd ) View more	Negative	12 Sep 2026
				carboplatin/etoposide (CE)	kwgyngnmvc(hhyxwcdgby) = wwcjtnoina vdcvvnswsn (tlvsybylgd ) View more
WCLC2026	Not Applicable	Locally Advanced Lung Carcinoma Adjuvant	58	Atezolizumab	kogtopfqzs(frzlzkdlie) = ekwaiqkbsb fnkcfytuyf (zjkimreyrf ) View more	Positive	12 Sep 2026
				Conventional therapy (platinum-based chemotherapy or observation)	kogtopfqzs(frzlzkdlie) = csmndrvwzb fnkcfytuyf (zjkimreyrf ) View more
WCLC2026	Not Applicable	RIT1-A77G \| ARID1A \| RIT1-M90I ... View more	3	pembrolizumab	jgmvtvtwxp(ksvyouqijx) = easwekvtrz tfggfxjhrh (vowrrqqpem )	Negative	12 Sep 2026
				Lazertinib/placebo and osimertinib/placebo (RIT1 amplified LUAD with bone metastasis)	jgmvtvtwxp(ksvyouqijx) = bddzkcfiaq tfggfxjhrh (vowrrqqpem )

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.

login

or

view full example data

Understand key drug designations in just a few clicks with Synapse.

Atezolizumab

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Biosimilar

Regulation